Related references
Note: Only part of the references are listed.LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928)
D. Planchard et al.
ANNALS OF ONCOLOGY (2017)
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Clemens Krepler et al.
CLINICAL CANCER RESEARCH (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations
Claire Tissot et al.
LUNG CANCER (2016)
A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation
Maria Sereno et al.
ANTI-CANCER DRUGS (2015)
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
Gang Zheng et al.
BMC CANCER (2015)
Path Forward for RAF Therapies: Inhibition of Monomers and Dimers
Robert L. Kortum et al.
CANCER CELL (2015)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
Zhan Yao et al.
CANCER CELL (2015)
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
Maria Romina Girotti et al.
CANCER CELL (2015)
Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer
S. Ali et al.
EUROPEAN JOURNAL OF CANCER (2015)
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Douglas B. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2015)
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Oliver Gautschi et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma
S. Schmid et al.
LUNG CANCER (2015)
BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma
Jennifer Roux et al.
MELANOMA RESEARCH (2015)
RAF inhibitors that evade paradoxical MAPK pathway activation
Chao Zhang et al.
NATURE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers
Jin Sung Jang et al.
SCIENTIFIC REPORTS (2015)
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Sarah J. Welsh et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Clinicopathologic Features and Outcomes of Patients With Lung Adenocarcinomas Harboring BRAF Mutations in the Lung Cancer Mutation Consortium
Liza C. Villaruz et al.
CANCER (2015)
Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
Monika Joshi et al.
PLOS ONE (2015)
Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma
Brian J. Capaldo et al.
PLOS ONE (2015)
Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations
T. Kinno et al.
ANNALS OF ONCOLOGY (2014)
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
Douglas B. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
Anya M. Litvak et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
Sara D. Robinson et al.
LUNG CANCER (2014)
BRAF-mutations in non-small cell lung cancer
Odd Terje Brustugun et al.
LUNG CANCER (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib
Andrea Forschner et al.
MELANOMA RESEARCH (2014)
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
Luping Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy
Ricarda Merten et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2014)
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
Anna A. Marusiak et al.
NATURE COMMUNICATIONS (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients
M. Ilie et al.
ANNALS OF ONCOLOGY (2013)
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
Stephanie Cardarella et al.
CLINICAL CANCER RESEARCH (2013)
BRAF Inhibitor-Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition
Miles C. Andrews et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma
Solange Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy
Imke Satzger et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non-Small-Cell Lung Cancer
Charles M. Rudin et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling
Alyson K. Freeman et al.
MOLECULAR CELL (2013)
Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
Jessie Villanueva et al.
CELL REPORTS (2013)
Vemurafenib and Radiosensitization
Lise Boussemart et al.
JAMA DERMATOLOGY (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib
Oliver Gautschi et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Margaret K. Callahan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BRAFL597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
Kimberly Brown Dahlman et al.
CANCER DISCOVERY (2012)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Harboring BRAF Mutations
Antonio Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paul K. Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
BRAF as therapeutic target in melanoma
Claudia Wellbrock et al.
BIOCHEMICAL PHARMACOLOGY (2010)
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Hong Yang et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
A dimerization-dependent mechanism drives RAF catalytic activation
Thanashan Rajakulendran et al.
NATURE (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding et al.
NATURE (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
New insight into BRAF mutations in cancer
Nathalie Dhomen et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions
S Yoon et al.
GROWTH FACTORS (2006)
Regulation and role of Raf-1/B-Raf heterodimerization
LK Rushworth et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601
BH Zhang et al.
EMBO JOURNAL (2000)
Share Paper
